Spyre Therapeutics, Inc. SYRE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $60.41M+35.3% | $44.64M-1.3% | $45.25M+12.7% | $40.15M-3.6% | $41.62M-17.5% | ||
| $15.23M+21.5% | $12.53M+7.7% | $11.64M-1.3% | $11.79M-1.3% | $11.94M+10.9% | ||
| $45.64M-20.2% | $57.17M+0.5% | $56.89M+35.7% | $41.94M-21.7% | $53.57M-12.5% | ||
| -$45.64M+20.2% | -$57.17M-0.5% | -$56.89M-35.7% | -$41.94M+21.7% | -$53.57M+12.5% | ||
| -$23.36M— | $0-100% | $45.71M+776% | $5.22M-40.6% | $8.78M+77.1% | ||
| -$69.01M-10.4% | -$62.53M-459% | -$11.18M+69.5% | -$36.72M+18.0% | -$44.79M+20.4% | ||
| $0— | $0— | $0— | $0+100% | -$15K-1,600% | ||
| -$69.01M-10.4% | -$62.53M-459% | -$11.18M+69.5% | -$36.72M+18.0% | -$44.77M+20.5% | ||
| -$0.740.0% | -$0.74-393% | -$0.15+69.4% | -$0.49+18.3% | -$0.60-150% | ||
| -$45.64M+20.2% | -$57.17M-0.5% | -$56.89M-35.7% | -$41.94M+21.7% | -$53.57M+12.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Spyre Therapeutics, Inc. profitable?
- Spyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $179.4M over the trailing twelve months, a -52939.7% net margin.
- What is Spyre Therapeutics, Inc.'s earnings per share?
- Spyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.12.
- Where does Spyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.